Moleculin Biotech (MBRX) Stock: Trade Alert!

Moleculin Biotech Inc (NASDAQ: MBRX)

Shares of MBRX are trading sharply higher in Tuesday morning trading, with shares higher by over 36% on unusually strong volume for this time of day. Our friends at Trade Ideas provided a real time price alert for MBRX.

MBRX stock has been weak prior to today, with the shares giving back over 40% of their early November gains. However, with volume substantially higher than normal and with the accompanied share price acceleration, investors should keep an eye on MBRX for company specific news, which CNA Finance will provide on a real-time basis.

MBRX Opportunity In Treating AML

As CNA Finance followers know from our prior coverage of MBRX, the company offers compelling reasons to consider the stock as part of their small cap portfolio.

MBRX’s lead drug, Annamycin, is an anthracycline intended for the treatment of relapsed or refractory AML. Anthracycline, which is used mostly in combination therapies has been used to treat AML from as far back as 1970. Despite that fact, even while enormous advances have been made in the treatment of cancer and other diseases, the advancements to treat AML with anthracycline has not improved very much at all. In fact, it is estimated that the use of anthracycline in combination therapy delivers the similar 20% success rate for induction therapy as back in 1970. This is where Annamycin can make the difference.

Currently, the only reliable option for acute leukemia patients is a bone marrow transplant, which has proven to be successful in treating a significant number of patients. However, to get to the point where a patient can qualify for the bone marrow transplant, they must be treated with the anthracycline compound, a treatment called induction therapy. And with doxorubicin being the current drug at hand, annamycin can certainly prevail in capturing an enormous piece of market share.

In a previous phase I study, annamycin demonstrated efficacy in 8 of 16 patients, with 6 having a complete clearing of leukemic blasts. A 30-patient phase I/II study in acute lymphocytic leukemia demonstrated similar efficacy.

CNA Finance will keep followers appraised of any new price alerts or company-specific news.

Disclosure: This article was written by Kenny Soulstring, and it reflects my own opinions and unique articulation. This article is not intended to offer investing advice, guarantee 100% accurate predictions or to be interpreted as providing a personal recommendation. What I can guarantee, though, is accurate research, thoughtful analysis and an enthusiasm about any stock that I cover.

While I seek to uncover emerging companies that I feel have true value and potential, it’s important that investors assign an appropriate time horizon to each of their investments, understanding that emerging companies need time to mature.

I wrote this article myself and it includes my own research and expresses my own opinions. I am not receiving compensation for it (other than from CNA Finance). I have no business relationship with any company whose stock is mentioned in this article.

Additional Disclosure: I have no position in any stock mentioned and no plans to initiate any positions within the next 72 hours.

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required

[Image Courtesy of Flickr]

Leave a Comment